{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:19:57Z","timestamp":1791958797745,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673062"],"award-info":[{"award-number":["81673062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.intimp.2019.106045","type":"journal-article","created":{"date-parts":[[2019,12,25]],"date-time":"2019-12-25T15:43:46Z","timestamp":1577288626000},"page":"106045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating I\u03baB\u03b6"],"prefix":"10.1016","volume":"79","author":[{"given":"Jie","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FangYuan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiQiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2019.106045_b0005","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2019.106045_b0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2019.106045_b0015","doi-asserted-by":"crossref","first-page":"15631","DOI":"10.1038\/s41598-017-15892-7","article-title":"The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function","volume":"7","author":"Pfaff","year":"2017","journal-title":"Sci. Rep-UK"},{"key":"10.1016\/j.intimp.2019.106045_b0020","doi-asserted-by":"crossref","DOI":"10.1111\/exd.13871","article-title":"IL-17A synergistically enhances TLR3-mediated IL-36gamma production by keratinocytes: a potential role in injury-amplified psoriatic inflammation","author":"Liu","year":"2019","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.intimp.2019.106045_b0025","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/intimm\/dxw011","article-title":"IL-17A plays a central role in the expression of psoriasis signature genes through the induction of I\u03baB-\u03b6 in keratinocytes","volume":"28","author":"Tawa","year":"2016","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2019.106045_b0030","doi-asserted-by":"crossref","first-page":"E5825","DOI":"10.1073\/pnas.1509971112","article-title":"I\u03baB\u03b6 is a key driver in the development of psoriasis","volume":"112","author":"Johansen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2019.106045_b0035","doi-asserted-by":"crossref","first-page":"10088","DOI":"10.1073\/pnas.1801377115","article-title":"IkappaBzeta is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytes","volume":"115","author":"Muller","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2019.106045_b0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cyto.2015.11.015","article-title":"I\u03baB\u03b6: a key protein in the pathogenesis of psoriasis","volume":"78","author":"Johansen","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2019.106045_b0045","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.clindermatol.2017.10.013","article-title":"Psoriasis in the mature patient: therapeutic approach in the era of biologics","volume":"36","author":"Kostovi\u0107","year":"2018","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.intimp.2019.106045_b0050","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1007\/s00403-002-0371-6","article-title":"Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity","volume":"295","author":"Umezawa","year":"2003","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.intimp.2019.106045_b0055","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1346-8138.1999.tb03444.x","article-title":"Treatments of generalized pustular psoriasis: a multicenter study in Japan","volume":"26","author":"Ozawa","year":"1999","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2019.106045_b0060","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1468-3083.2011.03993.x","article-title":"Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review","volume":"25","author":"Sbidian","year":"2011","journal-title":"J. Eur. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2019.106045_b0065","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jaad.2011.01.032","article-title":"Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation","volume":"67","author":"Robinson","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2019.106045_b0070","first-page":"669","article-title":"Generalized pustular psoriasis (Zumbusch): a French epidemiological survey","volume":"16","author":"Augey","year":"2006","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.intimp.2019.106045_b0075","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/pde.12296","article-title":"Pustular psoriasis in childhood and adolescence: a 20-year single-center experience","volume":"31","author":"Popadic","year":"2014","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.intimp.2019.106045_b0080","first-page":"645","article-title":"S3 Guideline for the treatment of psoriasis vulgaris, update \u2013 short version part 1 \u2013 systemic treatment","volume":"16","author":"Nast","year":"2018","journal-title":"JDDG: J. der Deutschen Dermatologischen Gesellschaft"},{"key":"10.1016\/j.intimp.2019.106045_b0085","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris \u2013 update 2015 \u2013 short version \u2013 EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J. Eur. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2019.106045_b0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archdermatol.2011.1410","article-title":"Consensus guidelines for the management of plaque psoriasis","volume":"148","author":"Hsu","year":"2012","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2019.106045_b0095","first-page":"1","article-title":"Efficacy of acitretin in severe psoriasis","volume":"8","author":"Geiger","year":"2003","journal-title":"Skin Therapy Lett."},{"key":"10.1016\/j.intimp.2019.106045_b0100","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/ijd.14246","article-title":"Review of safety and efficacy of approved systemic psoriasis therapies","volume":"58","author":"Kaushik","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.intimp.2019.106045_b0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1155\/2013\/530429","article-title":"Palmitic acid induces production of proinflammatory cytokines Interleukin-6, Interleukin-1, and Tumor Necrosis Factor- via a NF-B-dependent mechanism in HaCaT keratinocytes","volume":"2013","author":"Zhou","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.intimp.2019.106045_b0110","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2147\/DDDT.S194765","article-title":"Cathepsin G cleaves and activates IL-36gamma and promotes the inflammation of psoriasis","volume":"13","author":"Guo","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.intimp.2019.106045_b0115","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/jid.2013.230","article-title":"The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist","volume":"133","author":"Sugiura","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2019.106045_b0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jdermsci.2014.02.006","article-title":"The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants","volume":"74","author":"Sugiura","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.intimp.2019.106045_b0125","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/imr.12610","article-title":"Regulation and function of interleukin-36 cytokines","volume":"281","author":"Bassoy","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2019.106045_b0130","doi-asserted-by":"crossref","first-page":"42594","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity","volume":"286","author":"Towne","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2019.106045_b0135","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/ijd.12365","article-title":"Acitretin in psoriasis: an evolving scenario","volume":"53","author":"Dogra","year":"2014","journal-title":"Int. J. Dermatol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919318302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919318302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T18:42:21Z","timestamp":1727289741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919318302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":27,"alternative-id":["S1567576919318302"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.106045","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating I\u03baB\u03b6","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.106045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106045"}}